Results 71 to 80 of about 22,351 (243)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod

Neurology: Neuroimmunology & Neuroinflammation, 2022
Objectives To evaluate whether a third vaccination shows an added effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell responses in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
V. Palomares Cabeza, L. Kummer, L. Wieske, Ruth R. Hagen, M. Duurland, Veronique A. L. Konijn, K. V. van Dam, E. Stalman, C. E. van de Sandt, L. Boekel, N. Verstegen, M. Steenhuis, T. Rispens, S. Tas, G. Wolbink, J. Killestein, T. Kuijpers, S. V. van Ham, F. Eftimov, A. Brinke, Z. V. van Kempen   +20 more
semanticscholar   +1 more source

Incidence of uveitis and macular edema among patients taking fingolimod 0.5 mg for multiple sclerosis

Journal of Ophthalmic Inflammation and Infection, 2020
Background Patients with multiple sclerosis (MS) have a higher incidence of uveitis compared with the general population. Fingolimod, a first line disease modifying drug used in multiple sclerosis, may cause macular edema and thus requires ophthalmic ...
Scott Joseph Sonne, Bradley Thomas Smith
doaj   +1 more source

Porcine kidney xenotransplantation: From primate models to clinical reality

Animal Models and Experimental Medicine, EarlyView.
In the face of a critical shortage of human donor kidneys for end‐stage renal disease patients, porcine kidney xenotransplantation has emerged as a viable solution. This field has navigated major hurdles, including immune rejection, physiological incompatibilities, potential biomechanical differences and the risk of cross‐species infection. To overcome
Zihang Guo, Ling Zhang, Shoulong Deng, Chuan Qin   +3 more
wiley   +1 more source

Fingolimod: therapeutic mechanisms and ocular adverse effects. [PDF]

, 2017
Fingolimod is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). We aim to review the published literature on ocular manifestations of fingolimod therapy and their possible underlying mechanisms.
P Mandal, W Fusi-Rubiano, Gupta, A, Y Yang, Mandal, P, P A Keane, Yang, Y, Keane, PA, Fusi-Rubiano, W, A Gupta   +9 more
core   +1 more source

Clinical effectiveness of fingolimod treatment.

, 2022
Clinical effectiveness of fingolimod treatment.
Dániel Sandi (6252581), Attila Csányi (12446837), Enikő Dobos (12191539), Krisztina Bencsik (6252584), László Vécsei (336072), Judit Füvesi (12191521), Zsanett Fricska-Nagy (12191518), Krisztina Kovács (238775), László Horváth (12446834), Péter Ács (12446828), Botond Cseh (12197708), Zsuzsanna Nagy (64689), Tünde Csépány (10272518), Csilla Rózsa (12446831), Tamás Biernacki (12191524), Tamás Zsigmond Kincses (3130233)   +15 more
core   +1 more source

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

Annals of Neurology, EarlyView.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell, Sebastian Hedberg, Fredrik Piehl   +2 more
wiley   +1 more source

The efficacy and safety of fingolimod plus standardized treatment versus standardized treatment alone for acute ischemic stroke: A systematic review and meta‐analysis

Pharmacology Research & Perspectives, 2022
Acute ischemic stroke (AIS) is the most common type of stroke. Fingolimod is a sphingosine analog that acts on sphingosine‐1‐phosphate receptors (S1PR).
Peng Bai, Runxiu Zhu, Ping Wang, Feng Jiang, Jin Zhen, Yuan Yao, Chen-hui Zhao, Zihong Liang, Meiling Wang, Bin Liu, Min Li, Nan Li, Jun Yuan   +12 more
semanticscholar   +1 more source

Análisis de minimización de costes entre fingolimod y natalizumab en segunda línea de tratamiento de esclerosis múltiple remitente-recurrente

Neurología, 2014
Resumen: Introducción: Actualmente, existe una ausencia de evaluaciones económicas en el manejo de la esclerosis múltiple remitente-recurrente en segunda línea.
C. Crespo, G. Izquierdo, A. García-Ruiz, M. Granell, M. Brosa   +4 more
doaj   +1 more source

Beneficial effects of fingolimod in MS patients with high serum Sema4A levels. [PDF]

PLoS ONE, 2018
We previously demonstrated that patients with multiple sclerosis (MS) of high serum Sema4A levels are resistant to IFN-β therapy. To further elucidate the role of serum Sema4A as a biomarker for therapeutic stratification in MS patients, it is important ...
Toru Koda, Akiko Namba, Yuji Nakatsuji, Masaaki Niino, Yusei Miyazaki, Tomoyuki Sugimoto, Makoto Kinoshita, Kazushiro Takata, Kazuya Yamashita, Mikito Shimizu, Toshiyuki Fukazawa, Atsushi Kumanogoh, Hideki Mochizuki, Tatsusada Okuno   +13 more
doaj   +1 more source

Fingolimod

Reactions Weekly, 2012
Hoofnagle JH.
europepmc   +2 more sources